Montelukast: Pharmacology, Safety, Tolerability and Efficacy
Clinical Medicine. Therapeutics · 2009
DOI: 10.4137/cmt.s1147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, 2009. Verfasst von Michael S. Benninger und 1 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
Allergic rhinitis and asthma are common disorders effecting large percentages of the population of Western countries. There are multiple treatment options available for allergic rhinitis and asthma and stepwise approaches to therapy have been recommended. Montelukast is a cysteinyl leukotriene receptor antagonist that has been found to be effective both in the treatment of allergic rhinitis and asthma. This paper will describe the pharmacology, safety, efficacy and tolerability of montelukast. It will examine the comparative efficacy of montelukast to other medications for the treatment of allergic rhinitis and asthma, as well as discuss the recent studies of combination therapy.
Zitieren
APA
Benninger, M. S., & Waters, H. (2009). Montelukast: Pharmacology, Safety, Tolerability and Efficacy. Clinical Medicine. Therapeutics. https://doi.org/10.4137/cmt.s1147
Vancouver
Benninger MS, Waters H. Montelukast: Pharmacology, Safety, Tolerability and Efficacy. Clinical Medicine. Therapeutics. 2009. doi:10.4137/cmt.s1147
BibTeX
@article{Benninger2009,
author = {Benninger, Michael S. and Waters, Heather},
title = {Montelukast: Pharmacology, Safety, Tolerability and Efficacy},
journal = {Clinical Medicine. Therapeutics},
year = {2009},
doi = {10.4137/cmt.s1147}
}
EUVIMED